Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Want to cut your energy bills? Here’s how five experts are doing it 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SOUTH SAN FRANCISCO, Calif., March 01, 2017 -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the following conferences in March:
- Cowen and Company’s 37th Annual Health Care Conference on Tuesday, March 7, 2017, at 9:20 a.m. Eastern Time in Boston.
- Oppenheimer’s 27th Annual Healthcare Conference on Wednesday, March 22, 2017, at 1:35 p.m. Eastern Time in New York.
Both presentations will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected] 415.946.1087
